Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A - Wikidata - awgldk - TriplyDB

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

http://www.wikidata.org/entity/Q35771337

about

Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Disease-specific cardiovascular positron emission tomography/magnetic resonance imaging: a brief review of the current literature Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study.The heart in Anderson-Fabry disease and other lysosomal storage disorders.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance.Novel therapeutic targets for the treatment of Fabry disease.Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.Fibrosis: a key feature of Fabry disease with potential therapeutic implications Early cardiac changes in children with anderson-fabry disease.Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.Fabry disease-often seen, rarely diagnosed.Quantitative cardiac positron emission tomography: the time is coming!Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease Decreased nitric oxide bioavailability in a mouse model of Fabry disease.Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.Nuclear cardiac imaging in hypertrophic cardiomyopathy.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Coronary microvascular dysfunction in primary cardiomyopathies.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.Fabry's disease: an example of cardiorenal syndrome type 5.A focus on the prognosis and management of ischemic heart disease in patients without evidence of obstructive coronary artery disease.Current perspectives in coronary microvascular dysfunction.Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease.Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests.Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease.Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.Fabry disease and Factor V Leiden: a potent vascular risk combination.Therapeutic goals in the treatment of Fabry disease.Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.Anderson-Fabry disease in heart failure

P2860

Q24200877-ED271CDE-EEB7-48B7-BF9C-52976F232557 Q24235483-1FDA1B41-233B-49E1-8346-DFFBC5D52E79 Q26471010-A31D6059-C435-4FD3-9A37-7CC291DE8305 Q26739729-30929087-BBD2-456D-9F8D-C96262A95DE3 Q34022070-0A973F86-C292-4C51-B997-4A13ED3E221B Q34257466-4EF06830-84B6-4949-B498-E65C161CE12D Q35093085-92A59FEC-1137-4A6F-9DA6-528B72ECF0E2 Q35664621-4D760878-1A02-437A-9ED3-363AF5F95796 Q35773435-B528C078-F101-4C49-B2F7-5E59B0BF653D Q36309032-B2E81486-EC9B-43FF-BC16-5427AE4AD1AB Q36769403-1912E180-FFF4-4F1A-8993-C87AEE8EFD14 Q36822452-80A2E601-7F74-4603-A3FF-9C39C464D9F4 Q37073303-3E18BE67-B994-4DED-B6D9-99C42A1437C1 Q37113004-651610F7-747E-44E0-9571-B9F1E5550F41 Q37127636-7EE0F669-9750-459F-A1B3-3C422F85A818 Q37162532-32E83F11-5D37-4760-B7D3-DEE76D1DF980 Q37246955-EECFF9E2-9A67-4531-9FD3-22B223A3CDF7 Q37288099-22F6FCFA-D293-4F74-925B-E34995717FA2 Q37290507-2A69D92E-FEC3-47B5-AEE0-1F3A57E5162C Q37330561-C0E641C0-187F-4BF2-A8F2-DFDACAD5745B Q37347258-D3778EA9-3E6F-47FE-82BF-0A39208AEAD0 Q37782285-47AC5F11-FC8E-40F1-B98C-9104C4A83622 Q37801828-1A506B10-C886-4562-AB10-FCAF35AFF0DC Q38125666-7E33C071-FE96-4FD6-A03D-8F8C87E958B1 Q38184922-7161AA60-C969-4944-9FA3-3E9368ECB06A Q38230252-7A153CB7-4D08-4964-AB90-3EC95D84061D Q38558725-04D2119F-ECF2-49ED-A952-DAA6160E0E1F Q38574181-38F23BDF-CAEB-4F75-BB0A-CCB80A96D21A Q39038913-1EAFE8B7-0EAF-465F-A2A3-6D395CD372C9 Q39042794-DF6C731F-4246-432B-B05B-2602F58CFE7F Q39304682-01AB9E5B-828D-4B70-B4FD-0A8820AB67D6 Q39347577-8FC39813-264C-40FC-B8BF-32D2221FA181 Q41200738-DB19A627-8E47-4BEE-A913-0033BDFB423B Q41364439-B78E7F4F-F823-46EA-AFE4-F2E107C117BF Q46587509-C47485BB-F36C-4BDE-955A-3C890DD12110 Q48664517-4D989DED-53EF-490A-8F2A-F4768E70FCD2 Q50436079-8084D136-E010-431E-A982-801C2223CE40 Q51228133-018DF006-CA9F-4493-8D1A-CF9307DAD96D Q51770360-D1E628DF-1850-4845-A6D5-DD9C4E17EE22 Q56807662-D2591DE1-D2D9-4443-B819-3583D671B7AF

P2860

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

http://www.wikidata.org/entity/Q35771337

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@ast

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@en

type

label

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@ast

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@en

prefLabel

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@ast

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@en

P1433

Q35771337-2DB77946-7C16-49BD-A4EE-2F6FA13815B1

P1476

Q35771337-383D1AFA-2403-4016-A92E-0CB6A2657D64

P2093

Q35771337-06BF6397-037D-4B76-B7AB-BCEA9E91B934

Q35771337-0A882840-C111-4175-822D-B3EA7177C218

Q35771337-1A4D39B6-E9AF-4D6A-AFFD-0587BFA78B8A

Q35771337-583A90CA-EA47-44C1-BFFA-C62C2C99990E

Q35771337-6637E459-42C8-43BA-AD87-DCE1D816E0EE

Q35771337-6CE87E41-6C2B-4C24-BAF2-27A3F2DF6029

Q35771337-6D8A247E-DF82-4391-936B-2C29E23AE2AB

Q35771337-AB357E1B-9DB7-4747-8AF0-A372A70F56C7

Q35771337-C4044226-E032-40A2-AC76-44B58AC24994

Q35771337-DEC45238-EDB9-4DC1-8241-5B539D6A1D45

P2860

Q35771337-134679BF-EDCF-449A-9CD5-FFCA20FD9173

Q35771337-1825BC08-98DF-4A94-843E-221BF2B65376

Q35771337-41814F84-7329-4690-BFB8-7AD4FDDC10C0

Q35771337-5D5966E5-8E3E-4928-898A-89DEDA716F2D

Q35771337-60FF444A-49CC-4C1A-A9C4-671B217526FA

Q35771337-6BAA8EF7-DC1A-49E3-BC49-3F6B62D5EE8D

Q35771337-6EAC9F74-3AD5-4466-8780-9F24B606AEF7

Q35771337-771E71A0-5188-45AC-8371-2C581E462B70

Q35771337-82ECACA2-1F1B-4FA0-AB15-FD4D2AF02576

Q35771337-A25475E6-E28E-4189-83FC-769F090A68CB

P304

Q35771337-2B968D6E-D1BC-44BE-ACDB-7EA10D2627D1

P31

Q35771337-FA871329-F4EC-4FAA-AC57-52C11E00BBDC

P356

Q35771337-DCF37F86-4305-4E0B-8E3B-75078ECBF68D

P407

Q35771337-CC57DBC5-B263-4A74-867A-2C65B520CB67

P433

Q35771337-D022B168-4DB7-4946-9081-7B3C93F6AEBE

P478

Q35771337-A9F0B8FB-7671-41EA-9024-29E253237B2F

P577

Q35771337-5602B411-1B3E-4306-9F98-4CCF01B6BF70

P5875

Q35771337-84A31CFE-B312-4F52-8BDC-D436A02EE84F

P698

Q35771337-67A3DA7A-D501-4260-813A-F4FEBDFF12BF

P932

Q35771337-93F9B836-B0EC-4620-AF92-606213A7A107

P356

HRT.2004.054015

P1433

P1476

Coronary microvascular dysfunc ...... ent with alpha galactosidase A

@en

P2093

B Sachdev

http://www.w3.org/2001/XMLSchema#string

H Kindler

http://www.w3.org/2001/XMLSchema#string

J S Shah

http://www.w3.org/2001/XMLSchema#string

M T Tome

http://www.w3.org/2001/XMLSchema#string

O E Rimoldi

http://www.w3.org/2001/XMLSchema#string

P G Camici

http://www.w3.org/2001/XMLSchema#string

P Lee

http://www.w3.org/2001/XMLSchema#string

P M Elliott

http://www.w3.org/2001/XMLSchema#string

R Thaman

http://www.w3.org/2001/XMLSchema#string

W J McKenna

http://www.w3.org/2001/XMLSchema#string

P2860

An atypical variant of Fabry's disease with manifestations confined to the myocardium

Enhanced endothelium-dependent vasodilation in Fabry disease

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

The natural history of left ventricular systolic function in Anderson-Fabry disease.

Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy

Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.

Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries.

Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

P304

357-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.2004.054015

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7673949

http://www.w3.org/2001/XMLSchema#string

P698

16085718

http://www.w3.org/2001/XMLSchema#string

P932

1860797

http://www.w3.org/2001/XMLSchema#string